Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Update on the new EUSOMA quality indicators for breast cancer
Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )
3 Feb 2022
The optimal approach after neoadjuvant treatment: The Lucerne toolbox
Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
The optimal approach after neoadjuvant treatment: The Lucerne toolbox ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )
3 Feb 2022
Lung cancer in India
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
3 Feb 2022
The global impact of the FDA's changing approval standards
Dr Bishal Gyawali - Queen's University, Kingston, Canada
The global impact of the FDA's changing approval standards ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
2 Feb 2022
Tumour agnostic treatments in GI cancer
Dr Nicola Normanno and Dr Katja Schmitz
Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )
1 Feb 2022
ecancer-AORTIC special issue on cancer research training in Africa
Dr Solomon Rotimi - Covenant University, Ota, Nigeria
ecancer-AORTIC special issue on cancer research training in Africa ( Dr Solomon Rotimi - Covenant University, Ota, Nigeria )
27 Jan 2022
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs pl...
Prof Peter Schmid - Queen Mary University of London, London, United Kingdom
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC ( Prof Peter Schmid - Queen Mary University of London, London, United Kingdom )
27 Jan 2022
Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract...
Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Kore...
Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )
27 Jan 2022
Early treatment discontinuation and early oxaliplatin discontinuation for stage ...
Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France
Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )
27 Jan 2022
HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients...
Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA
HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )
27 Jan 2022
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatme...
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2022
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC
Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
20 Jan 2022